Class information for:
Level 1: HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
13544 765 40.4 87%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
451 15419 HER 2//TRASTUZUMAB//LAPATINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 Author keyword 5 15% 4% 32
2 ADVANCED METASTATIC DISEASE Author keyword 2 67% 0% 2
3 ANTI EGF RECEPTOR ANTIBODY Author keyword 2 67% 0% 2
4 DOMINANT NEGATIVE STRATEGY Author keyword 2 67% 0% 2
5 GENE PROTEIN ASSAY Author keyword 2 67% 0% 2
6 GASTROESOPHAGEAL CANCER Author keyword 2 14% 1% 11
7 HOSP UNIV MADRID SANCHINARRO Address 1 38% 0% 3
8 CANC COMPAN DIAGNOST Address 1 100% 0% 2
9 HER2 POSITIVE GASTRIC CANCER Author keyword 1 50% 0% 2
10 HUMAN EPIDERMAL GROWTH FACTOR 2 HER2 Author keyword 1 50% 0% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 5 15% 4% 32 Search HUMAN+EPIDERMAL+GROWTH+FACTOR+RECEPTOR+2 Search HUMAN+EPIDERMAL+GROWTH+FACTOR+RECEPTOR+2
2 ADVANCED METASTATIC DISEASE 2 67% 0% 2 Search ADVANCED+METASTATIC+DISEASE Search ADVANCED+METASTATIC+DISEASE
3 ANTI EGF RECEPTOR ANTIBODY 2 67% 0% 2 Search ANTI+EGF+RECEPTOR+ANTIBODY Search ANTI+EGF+RECEPTOR+ANTIBODY
4 DOMINANT NEGATIVE STRATEGY 2 67% 0% 2 Search DOMINANT+NEGATIVE+STRATEGY Search DOMINANT+NEGATIVE+STRATEGY
5 GENE PROTEIN ASSAY 2 67% 0% 2 Search GENE+PROTEIN+ASSAY Search GENE+PROTEIN+ASSAY
6 GASTROESOPHAGEAL CANCER 2 14% 1% 11 Search GASTROESOPHAGEAL+CANCER Search GASTROESOPHAGEAL+CANCER
7 HER2 POSITIVE GASTRIC CANCER 1 50% 0% 2 Search HER2+POSITIVE+GASTRIC+CANCER Search HER2+POSITIVE+GASTRIC+CANCER
8 HUMAN EPIDERMAL GROWTH FACTOR 2 HER2 1 50% 0% 2 Search HUMAN+EPIDERMAL+GROWTH+FACTOR+2+HER2 Search HUMAN+EPIDERMAL+GROWTH+FACTOR+2+HER2
9 TRANSTUZUMAB 1 50% 0% 2 Search TRANSTUZUMAB Search TRANSTUZUMAB
10 GASTROESOPHAGEAL ADENOCARCINOMA 1 33% 0% 3 Search GASTROESOPHAGEAL+ADENOCARCINOMA Search GASTROESOPHAGEAL+ADENOCARCINOMA

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 C ERBB 2 PROTEIN EXPRESSION 22 60% 3% 24
2 JUNCTION CANCER 14 100% 1% 7
3 C ERB B 2 9 33% 3% 22
4 GASTROESOPHAGEAL JUNCTION CANCER 8 60% 1% 9
5 CETUXIMAB PLUS OXALIPLATIN LEUCOVORIN 5 FLUOROURACIL 8 100% 1% 5
6 C ERBB 2 PROTEIN 6 17% 4% 34
7 INTERNISTISCHE ONKOLOGIE AIO 5 60% 1% 6
8 HUMAN STOMACH CANCER 5 50% 1% 7
9 LABEL PHASE 3 TRIAL 3 29% 1% 10
10 FGFR2 GENE AMPLIFICATION 3 50% 1% 4

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
HER2-positive gastric cancer 2014 19 68 40%
HER2 testing in gastric cancer: a practical approach 2012 93 25 40%
HER2 Testing in Gastric Cancer 2011 67 33 61%
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target 2008 313 47 43%
HER2 expression status in diverse cancers: review of results from 37,992 patients 2015 1 40 30%
HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma A Review of Histopathology, Diagnostic Testing, and Clinical Implications 2012 28 25 72%
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? 2014 11 80 29%
Advanced HER2-positive gastric cancer: Current and future targeted therapies 2013 17 86 41%
HER2 therapies and gastric cancer: A step forward 2013 11 41 51%
Targeted HER2 Treatment in Advanced Gastric Cancer 2010 75 45 64%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 HOSP UNIV MADRID SANCHINARRO 1 38% 0.4% 3
2 CANC COMPAN DIAGNOST 1 100% 0.3% 2
3 PATHOL MED MC81 1 50% 0.3% 2
4 JIANHU PEOPLES HOSP 1 40% 0.3% 2
5 MED ONCOL F MAGRASSI A LANZARA 1 40% 0.3% 2
6 AFFILIATED JIANHU HOSP 1 33% 0.3% 2
7 AGR FO T POLICY 1 50% 0.1% 1
8 ASIA EMERGING MARKET IMED 1 50% 0.1% 1
9 BIO MED MED 1 50% 0.1% 1
10 BIOREPOSITORY BIOMARKER ANAL 1 50% 0.1% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000208946 ADVANCED GASTRIC CANCER//S 1//METASTATIC GASTRIC CANCER
2 0.0000201552 HER 2//HER2 TESTING//POLYSOMY 17
3 0.0000197633 HUMAN CYTOGENET TOXICOL GENET//C KI RAS ONCOGENE//JOAO BARROS BARRETO UNIV HOSP
4 0.0000163960 C ERBB 2//HER 2 NEU//P185
5 0.0000125207 HER3//NUCLEAR EGFR//EGFR FAMILY
6 0.0000117040 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
7 0.0000110624 EGF POLYMORPHISM//GEFITINIB THERAPY//INTRON 1 POLYMORPHISM
8 0.0000094873 NIMOTUZUMAB//H R3//CETUXIMAB
9 0.0000059707 PANITUMUMAB//CETUXIMAB//METASTATIC COLORECTAL CANCER
10 0.0000058881 BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES